VAS101，一种新型姜黄素透皮制剂，可逆转衰老的一些临床特征-动脉网

VAS101, a Novel Curcumin Transdermal Formulation, Reverses Some Clinical Hallmarks of Aging

CISION 等信源发布 2025-03-17 23:02



可切换为仅中文







SUMMIT, N.J.

新泽西州萨米特

March 17, 2025

2025年3月17日

/PRNewswire/ -- In a new study published in the journal GeroScience, VAS101 (Vasceptor®), a

/PRNewswire/ -- 在《GeroScience》期刊发表的一项新研究中，VAS101（Vasceptor®），一种

novel curcumin transdermal formulation

新型姜黄素透皮制剂

developed by Vascarta Inc. (

由Vascarta Inc.开发（

Summit, NJ

新泽西州萨米特

, USA), when administered topically twice weekly i) restored physical and cognitive function in aged mice as well as improving markers of frailty; ii) reduced age associated inflammation (inflammaging) markers in multiple organs; iii) initiated tissue remodeling in aging hearts; and iv) lowered interleukin 11 (IL-11) expression in the kidney.

，美国），当每周两次局部给药时，i）恢复了老年小鼠的身体和认知功能，并改善了虚弱标志物；ii）减少了多个器官中与年龄相关的炎症（炎性衰老）标志物；iii）启动了老化心脏中的组织重塑；iv）降低了肾脏中白细胞介素11（IL-11）的表达。

The inhibition of IL-11 via a biologic was recently shown to increase the life span of mice [see Widjaja, A.A., et al, Inhibition of IL-11 signaling extends mammalian healthspan and lifespan. .

通过生物制品抑制IL-11最近被证明可以延长小鼠的寿命 [参见Widjaja, A.A., 等人，《抑制IL-11信号传导延长哺乳动物的健康寿命和寿命》。].

Nature

自然

，

632

(8023), pp.157-165]. The present study also demonstrated that topically applied VAS101 can accelerate restoration of vascular health as reflected in normalizing blood pressure in an endothelial dysfunction model.

(8023), 第157-165页]。本研究还表明，局部应用VAS101可以加速血管健康恢复，这在内皮功能障碍模型中表现为血压正常化。

Vascular health is generally regarded as key to general health with endothelial dysfunction responsible for many age-related system failures. VAS101 provides a unique mechanism for delivery of curcumin to the endothelial lining of those blood vessels that are essential for vascular health. VAS101 was shown in prior studies to effectively load red blood cells with curcumin (Curc-RBCs), improving both their .

血管健康通常被认为是整体健康的关键，内皮功能障碍是导致许多与年龄相关的系统故障的原因。VAS101提供了一种独特的机制，可以将姜黄素输送到对血管健康至关重要的血管内皮层。在之前的研究中，VAS101 被证明能有效将姜黄素加载到红细胞中（Curc-RBCs），从而改善它们的。

ex vivo

离体

stability and extending circulation time in a surrogate animal model. Curc-RBCs were also shown to cross the blood brain barrier and deactivate activated mast cells and microglia and, in turn, limit chronic pain and neuro-inflammation. Curc-RBCs are not targeted by immune cells nor, like many intravenously- administered drugs and nanoparticle delivery vehicles, subjected to hepatic first-pass effect, thus allowing for full and sustained systemic delivery of the active ingredient..

在替代动物模型中显示出稳定性和延长循环时间。Curc-RBCs还被证明能够穿越血脑屏障，使活化的肥大细胞和小胶质细胞失活，从而限制慢性疼痛和神经炎症。Curc-RBCs不会成为免疫细胞的目标，也不会像许多静脉注射药物和纳米颗粒递送载体那样受到肝脏首过效应的影响，从而实现活性成分的完全和持续的系统递送。

Unlike oral curcumin, which is poorly absorbed, rapidly cleared and otherwise entangled with albumin and other circulating proteins, VAS101, through its subsequent enrichment of Curc-RBCs, uniquely reaches the endothelial layer of smaller and narrower blood vessels that are most critical for organ and tissue health and function..

与口服姜黄素不同，VAS101通过后续富集Curc-RBCs，独特地到达对器官和组织健康及功能最为关键的较小和较窄血管的内皮层，而口服姜黄素吸收差、清除快，并且容易与白蛋白和其他循环蛋白纠缠。

The many positive effects of VAS101 are at least in part attributable to the known nitric oxide (NO) enhancing capability of curcumin. Curcumin delivery to small diameter blood vessels is an optimal strategy for improving vascular function by enhancing local levels of NO in the endothelium.

VAS101的许多积极效果至少部分归因于姜黄素已知的一氧化氮（NO）增强能力。将姜黄素输送到小直径血管是通过提高内皮中局部NO水平来改善血管功能的最佳策略。

Joel Friedman

乔尔·弗里德曼

, M.D., Ph.D., professor of microbiology & immunology and of medicine at Albert Einstein College of Medicine and Vascarta Scientific Founder and Head, Scientific Advisory Board, stated, 'Realizing curcumin's well-documented effects on general health have been limited by the ability to achieve sustained, therapeutic concentrations in target tissues.

医学博士、哲学博士，阿尔伯特·爱因斯坦医学院微生物学与免疫学及医学教授，Vascarta科学创始人兼科学顾问委员会主席表示：“姜黄素对整体健康的影响已得到充分证实，但其在靶组织中实现持续治疗浓度的能力受限。”

What has been needed is a safe, cost-effective, and easy to use formulation that can be deployed over an extended period of time that targets the appropriate tissues. Transdermal VAS101 (Vasceptor®) may fill this gap and provide a novel way to restore some key elements of vascular health and slow and possibly reverse the aging process.' [Dr.

所需要的是一种安全、经济高效且易于使用的制剂，可以在较长时间内使用并针对适当的组织。经皮VAS101（Vasceptor®）可能会填补这一空白，并提供一种恢复血管健康关键元素的新方法，减缓甚至可能逆转衰老过程。”[Dr.

Friedman is a co-author on the GeroScience paper and the inventor of VAS-101 which is exclusively licensed to Vascarta from the Albert Einstein College of Medicine (.

弗里德曼是《老年科学》论文的合著者，也是 VAS-101 的发明者，该产品由阿尔伯特·爱因斯坦医学院独家授权给 Vascarta。

Bronx, New York

纽约，布朗克斯

, USA)].

，美国）]。

Senior author

高级作者

Derek Huffman

德里克·哈夫曼

, Ph.D., professor of molecular pharmacology and of medicine and Co-Director of the Nathan Shock Center at Einstein, remarked, 'We observed that a short intervention with transdermal VAS101 resulted in a number of favorable effects on health in mice. This included improved aspects of health span such as exercise capacity and reduced frailty.

医学博士，爱因斯坦医学院分子药理学与医学教授，Nathan Shock中心联合主任评论道：“我们观察到，使用透皮VAS101进行短期干预在小鼠身上产生了多种健康方面的积极效果，这包括运动能力提升和虚弱减轻等健康寿命的改善方面。”

Based upon these data, VAS101 may have potential to be a safe and effective therapeutic to treat aging.'.

基于这些数据，VAS101可能具有成为一种安全有效的抗衰老治疗手段的潜力。

Dr.

博士

Richard Prince

理查德·普林斯

, Vascarta Chairman, CEO and President, said, 'As part of our commitment to making the health benefits of curcumin widely available, we are initiating human studies and will seek FDA approval of transdermal Vasceptor® in a range of conditions characterized by pain and inflammation.'

，Vascarta董事长、首席执行官兼总裁表示：“作为我们致力于使姜黄素的健康益处广泛可用的承诺的一部分，我们正在启动人体研究，并将在一系列以疼痛和炎症为特征的条件下寻求FDA对透皮Vasceptor®的批准。”

About Vascarta

关于Vascarta

Vascarta is a clinical stage pharmaceutical company exploring efficient transdermal delivery of pharmaceuticals to address several conditions with an initial focus on sickle cell disease and osteoarthritis. For those interested in learning more about Vascarta's clinical programs, contact Chairman, CEO & President Dr.

瓦斯卡尔塔是一家临床阶段的制药公司，致力于探索药物的有效透皮递送，以应对多种疾病，最初专注于镰状细胞病和骨关节炎。有兴趣了解更多关于瓦斯卡尔塔临床项目的信息，请联系董事长、首席执行官兼总裁博士。

。

Richard Prince

理查德·普林斯

在

rprince@vascarta.com

. Media requests should be directed to

媒体请求应指向

David Hymson

大卫·海姆森

在

dhymson@vascarta.com